No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study

BackgroundCurrently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally, causing an unprecedented pandemic. However, there is no specific antiviral therapy for coronavirus disease 2019 (COVID-19). We conducted a clinical trial to compare the effectiveness of three antiv...

Full description

Bibliographic Details
Main Authors: Yin-Qiu Huang, Sheng-Quan Tang, Xiao-Lei Xu, Yan-Ming Zeng, Xiao-Qing He, Yao Li, Vijay Harypursat, Yan-Qiu Lu, Yan Wan, Lu Zhang, Qiang-Zhong Sun, Nan-Nan Sun, Gui-Xue Wang, Zhong-Ping Yang, Yao-Kai Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Pharmacology
Subjects:
ribavirin
interferon-alpha
lopinavir/ritonavir
mild to moderate COVID-19
effectiveness and safety
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01071/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01071/full

Similar Items